no, 1% chance of being a blockbuster drug. Everything hinges on it being DMOAD, of which its Phase 3 trial isnt even going for. Based on the IND submission, its just another pain relief drug. They're trying to hint at DMOAD on low numbers but that means absolutely nothing to the medical community. If they were actually confident of DMOAD, why not add MRI into the equation? Evidence on biomarkers is suspect at best. might make for a nice headline if it sees a difference in any number of what, 15 that its testing for? will claim it as a win but reality is - barely means anything without radiographic evidence. my views
PAR Price at posting:
$1.82 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)